Tokio Marine Asset Management Co. Ltd. Grows Holdings in Moderna, Inc. (NASDAQ:MRNA)

Tokio Marine Asset Management Co. Ltd. raised its position in Moderna, Inc. (NASDAQ:MRNA) by 21.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,005 shares of the company’s stock after buying an additional 1,792 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Moderna were worth $995,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. First Pacific Financial acquired a new position in shares of Moderna during the 3rd quarter valued at about $27,000. Arlington Trust Co LLC increased its position in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC increased its position in Moderna by 54.1% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after purchasing an additional 180 shares in the last quarter. Archer Investment Corp increased its position in Moderna by 71.2% during the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after purchasing an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Moderna by 44.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after purchasing an additional 175 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the transaction, the director now directly owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. In the last three months, insiders sold 124,954 shares of company stock worth $13,158,776. 15.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of research analyst reports. HSBC reissued a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group reissued a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Canaccord Genuity Group increased their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Finally, William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $126.49.

Moderna Stock Performance

Moderna stock opened at $107.97 on Friday. The stock has a market cap of $41.34 billion, a P/E ratio of -8.70 and a beta of 1.62. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average of $102.54 and a 200-day moving average of $93.77. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.61 EPS. On average, analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.